INTENSITY THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $8.90M
- P/E (TTM)
- –
- Dividend yield
- –
About Intensity Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing localized intratumoral cancer therapies designed to stimulate systemic anti-cancer immune activation. Utilizing its proprietary DfuseRx discovery platform, the company creates formulations combining generic anti-cancer cytotoxic agents, such as cisplatin and vinblastine sulfate, with amphiphilic molecules to facilitate drug penetration and dispersion throughout dense tumor microenvironments. Its core product candidate, INT230-6, targets various solid tumors, including soft tissue sarcoma and early-stage or triple-negative breast cancer, serving cancer patients with major unmet medical needs.
The company conducts clinical trials across multiple countries, including the United States, Canada, Australia, France, Germany, Italy, Poland, and Switzerland. Up to 60 specialized sarcoma hospitals and research centers participate internationally in its studies. The provided text does not mention the location of the company's corporate headquarters.
Summary of the business section of Intensity Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INTENSITY THERAPEUTICS, INC.
- Headquarters
- Shelton, CT
- Address
- 1 Enterprise Drive, Suite 430 06484
- Phone
- (203) 221-7381
- Website
- intensitytherapeutics.com
- Employees
- 16, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, New York, New York
Stock & identifiers
- Ticker
- INTS
- Exchange
- Nasdaq
- IPO date
- Jun 30, 2023
- Shares outstanding
- 3M, Aug 7, 2026
- Public float
- $7.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Feb 19, 2026; 1-for-25 reverse, Feb 19, 2026
- SEC CIK
- 1567264
- CUSIP
- 45828J202
- ISIN
- US45828J2024
- EIN
- 46-1488089
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lewis H. Bender | President and CEO, Director | 118,549 |
| Joseph Talamo | Chief Financial Officer | 2,239 |
| John M. Wesolowski | Principal Accounting Officer | 7,102 |
| Thomas I. H. Dubin | Director | – |
| Mark A. Goldberg | Director | – |
| Daniel Donovan | Director | – |
| Emer Leahy | Director | – |
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had sixteen employees and contractors, including one with an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 5, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 6, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 20, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 19, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 30, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 30, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |